Back Pain News and Research RSS Feed - Back Pain News and Research

Back pain is a very common problem affecting almost all individuals at some point in their lives. Back pain most commonly affects the lower back although it can be felt anywhere along the spine. An individual may experience aching, tension and stiffness that lasts for only a few days or weeks, or these symptoms may continue for many months or even years.

In most cases, back pain does not have a specific or serious cause and is often referred to as 'non-specific' pain. However, the pain can be triggered or worsened by, for example, a poor sitting or standing posture or bending or lifting incorrectly.

The use of painkillers and keeping active is often sufficient for the condition to resolve within 12 weeks. If back pain lasts longer than this, in which case it is termed chronic pain, an individual should visit their doctor. If the back pain is accompanied by any one of a fever, unexplained weight loss, swelling in the back, chest pain, leg pain, loss of bladder or bowel control, inability to pass urine, or pain that is worse at night, then medical help should be sought immediately. These are termed 'red flag symptoms' and could be a sign of something more serious such as rheumatoid arthritis, a slipped disc or osteoporosis.

People can reduce their chance of developing back pain by engaging in regular exercise, particularly swimming or walking, taking care to bend from the knees and hips rather than the back and maintaining a good posture.
Better pain relief options for individuals with chronic back and leg pain

Better pain relief options for individuals with chronic back and leg pain

Chronic back and leg pain sufferers in search of better pain relief options may have a new choice. According to a study published in the Online First edition of Anesthesiology, the official medical journal of the American Society of Anesthesiologists, patients who received a novel high frequency form of spinal cord stimulation (SCS) therapy experienced significantly greater, long-term relief for both chronic back and leg pain, when compared to a traditional low frequency form of SCS therapy. [More]
Doctors of chiropractic points out dangers of heavy backpacks

Doctors of chiropractic points out dangers of heavy backpacks

As students savor the last precious weeks of summer vacation, parents are out making the final run for school supplies. So, parents, take note: When back-to-school shopping this year there is one essential item that requires very special attention: your child's backpack. [More]
Prolonged standing in workplace may lead to serious health consequences

Prolonged standing in workplace may lead to serious health consequences

Recent research has warned of the health detriments associated with sitting for long stretches of time at the office, but what about the nearly half of all employees worldwide who are required to stand for more than 75% of their workdays? Prolonged standing is associated with short-term adverse health issues, including reports of fatigue, leg cramps, and backaches, which can affect job performance and cause significant discomfort. [More]
Phase 3 ODYSSEY JAPAN trial of Praluent injection meets primary endpoint

Phase 3 ODYSSEY JAPAN trial of Praluent injection meets primary endpoint

Regeneron Pharmaceuticals, Inc. and Sanofi today announced that the Phase 3 ODYSSEY JAPAN trial of the investigational therapy Praluent® (alirocumab) Injection met its primary endpoint. [More]
Immune Pharmaceuticals amends licensing agreement with Endo Pharmaceuticals

Immune Pharmaceuticals amends licensing agreement with Endo Pharmaceuticals

Immune Pharmaceuticals, Inc. announced today that it has amended its 2003 Licensing Agreement with Endo Pharmaceuticals Inc., a subsidiary of Endo International plc. As a result, Immune will transfer to Endo its previously licensed patents related to the use of topical lidocaine in acute and chronic back pain and Endo will grant Immune a royalty-free, non-exclusive, fully transferable license to those patents. [More]
Study: Osteopathic manipulative therapy decreases low back pain by over 70% in postpartum women

Study: Osteopathic manipulative therapy decreases low back pain by over 70% in postpartum women

German researchers found osteopathic manipulative therapy (OMTh) decreased postpartum low back pain by over 70 percent in women who had given birth at least three months before beginning treatment, according to a new study published in July issue of the Journal of the American Osteopathic Association. [More]
STIOLTO RESPIMAT Inhalation Spray now available for treatment of COPD across the U.S.

STIOLTO RESPIMAT Inhalation Spray now available for treatment of COPD across the U.S.

Boehringer Ingelheim Pharmaceuticals, Inc. announced today that STIOLTO RESPIMAT (tiotropium bromide and olodaterol) Inhalation Spray is now available by prescription at pharmacies across the United States. [More]
ProfNet network experts available to discuss timely issues in your coverage area

ProfNet network experts available to discuss timely issues in your coverage area

Below are experts from the ProfNet network that are available to discuss timely issues in your coverage area. You can also submit a query to the hundreds of thousands of experts in our network – it's easy and free! [More]
MSD announces EC approval of SIMPONI (golimumab) for treatment of adult patients with nr-axial SpA

MSD announces EC approval of SIMPONI (golimumab) for treatment of adult patients with nr-axial SpA

MSD (Merck & Co., Inc., Kenilworth, New Jersey, USA) today announced that on 22 June the European Commission approved SIMPONI (golimumab) for the treatment of adult patients with severe, active non-radiographic axial spondyloarthritis (nr-axial SpA). [More]
The Lancet Oncology publishes results of CYRAMZA (ramucirumab) Phase III trial for HCC treatment

The Lancet Oncology publishes results of CYRAMZA (ramucirumab) Phase III trial for HCC treatment

Eli Lilly and Company announced that The Lancet Oncology has published results of the Phase III REACH trial that evaluated CYRAMZA (ramucirumab) as a second-line treatment for people with hepatocellular carcinoma (HCC), also known as liver cancer. While the REACH trial's primary endpoint of overall survival favored the CYRAMZA arm, it was not statistically significant. [More]
New form of talking therapy shows promise for people suffering from chronic low back pain

New form of talking therapy shows promise for people suffering from chronic low back pain

New research from Royal Holloway, University of London has found that a new form of talking therapy is a credible and promising treatment for people with chronic low back pain who are also suffering from related psychological stress. [More]
Men's poor health costs $36.9 billion a year for Canada

Men's poor health costs $36.9 billion a year for Canada

Canadian Men's Health Week is kicking off with an urgent message: Unhealthy lifestyle choices are running rampant, and they are costing this country an arm and a leg. [More]
NSAIDs significantly inhibit ovulation in women with mild musculoskeletal pain

NSAIDs significantly inhibit ovulation in women with mild musculoskeletal pain

The results of a study presented today at the European League Against Rheumatism Annual Congress (EULAR 2015) show that diclofenac, naproxen and etoricoxib significantly inhibit ovulation in women with mild musculoskeletal pain. Of the women receiving NSAIDs, only 6.3 percent (diclofenac), 25 percent (naproxen) and 27.3 percent (etoricoxib) ovulated, compared with 100 percent of the control group. [More]
Amgen to discuss data supporting Repatha BLA for high cholesterol treatment with FDA EMDAC

Amgen to discuss data supporting Repatha BLA for high cholesterol treatment with FDA EMDAC

Amgen today announced that the Company will discuss the data supporting the Repatha (evolocumab) Biologics License Application (BLA) for the treatment of high cholesterol with the U.S. Food and Drug Administration's (FDA) Endocrinologic and Metabolic Drugs Advisory Committee (EMDAC). [More]
New study finds growing use of CAM therapies among menopausal women

New study finds growing use of CAM therapies among menopausal women

The use of complementary and alternative medicine (CAM) is increasing for the treatment of menopausal symptoms but often without the guidance of a clinician. That's according to a new study reported online today in Menopause, the journal of the North American Menopause Society. [More]
People across the world are living longer but spending more time in ill health

People across the world are living longer but spending more time in ill health

People across the world are living longer but spending more time in ill health as rates of nonfatal diseases and injuries - including diabetes and hearing loss - decline more slowly than death rates, according to a new analysis of 301 diseases and injuries in 188 countries. [More]
GBD analysis shows over 95% of global population has health problems

GBD analysis shows over 95% of global population has health problems

Just one in 20 people worldwide (4·3%) had no health problems in 2013, with a third of the world's population (2·3 billion individuals) experiencing more than five ailments, according to a major new analysis from the Global Burden of Disease Study (GBD) 2013, published in The Lancet. [More]
Enzalutamide Phase 2 study for AR positive triple-negative breast cancer meets primary endpoint

Enzalutamide Phase 2 study for AR positive triple-negative breast cancer meets primary endpoint

Astellas Pharma Inc. announced that data from a Phase 2 study evaluating the investigational use of enzalutamide as a single agent for the treatment of advanced androgen receptor (AR) positive, triple-negative breast cancer (TNBC) were presented during an oral abstracts session at the 2015 American Society of Clinical Oncology (ASCO) Annual Meeting in Chicago. [More]
North American Spine Society issues formal coverage recommendation for MIS SI joint fusion

North American Spine Society issues formal coverage recommendation for MIS SI joint fusion

SI-BONE, Inc., a medical device company that pioneered the use of the iFuse Implant System®, a minimally invasive surgical (MIS) device indicated for fusion for certain disorders of the sacroiliac (SI) joint, announced that the North American Spine Society (NASS) has issued their formal coverage recommendation for MIS SI joint fusion titled "Percutaneous Sacroiliac Joint Fusion, Defining Appropriate Coverage Positions." [More]
Daratumumab achieves 29.2% overall response rate in heavily pre-treated patients with multiple myeloma

Daratumumab achieves 29.2% overall response rate in heavily pre-treated patients with multiple myeloma

Data from the international, multi-center, open-label, two-part, single-arm Phase 2 MMY2002 (SIRIUS) trial show treatment with single-agent daratumumab – an investigational, human anti-CD38 monoclonal antibody – achieved an overall response rate (ORR) of 29.2 percent (95% CI, 20.8-38.9), as assessed by an independent review committee, in heavily pre-treated patients with multiple myeloma. [More]
Advertisement
Advertisement